Want to see IN:APLLTD full AI Analyst Report?
Total Valuation
Alembic Pharmaceuticals Limited has a market cap or net worth of ₹165.96B. The enterprise value is ₹142.31K.
Market Cap₹165.96B
Enterprise Value₹142.31K
Share Statistics
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding196,563,130
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Alembic Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.40%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)10.40%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee4.26M
Profits Per Employee391.31K
Employee Count17,244
Asset Turnover0.84
Inventory Turnover1.61
Valuation Ratios
The current PE Ratio of Alembic Pharmaceuticals Limited is 23.4. Alembic Pharmaceuticals Limited’s PEG ratio is 1.23.
PE Ratio23.4
PS Ratio1.77
PB Ratio2.30
Price to Fair Value2.30
Price to FCF50.01
Price to Operating Cash Flow40.34
PEG Ratio1.23
Income Statement
In the last 12 months, Alembic Pharmaceuticals Limited had revenue of 73.45B and earned 6.75B in profits. Earnings per share was 34.33.
Revenue73.45B
Gross Profit33.10B
Operating Income8.00B
Pretax Income6.94B
Net Income6.75B
EBITDA11.06B
Earnings Per Share (EPS)34.33
Cash Flow
In the last 12 months, operating cash flow was 4.03B and capital expenditures -2.34B, giving a free cash flow of 1.69B billion.
Operating Cash Flow4.03B
Free Cash Flow1.69B
Free Cash Flow per Share8.59
Dividends & Yields
Alembic Pharmaceuticals Limited pays an annual dividend of ₹12, resulting in a dividend yield of 1.45%
Dividend Per Share₹12
Dividend Yield1.45%
Payout Ratio29.41%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-12.31%
50-Day Moving Average813.08
200-Day Moving Average781.24
Relative Strength Index (RSI)60.75
Average Volume (3m)22.74K
Important Dates
Alembic Pharmaceuticals Limited upcoming earnings date is Nov 10, 2026, TBA (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Alembic Pharmaceuticals Limited as a current ratio of 1.76, with Debt / Equity ratio of 0.00%
Current Ratio1.76
Quick Ratio0.79
Debt to Market Cap0.10
Net Debt to EBITDA1.11
Interest Coverage Ratio8.54
Taxes
In the past 12 months, Alembic Pharmaceuticals Limited has paid 231.20M in taxes.
Income Tax231.20M
Effective Tax Rate0.03
Enterprise Valuation
Alembic Pharmaceuticals Limited EV to EBITDA ratio is 12.90, with an EV/FCF ratio of 54.72.
EV to Sales1.94
EV to EBITDA12.90
EV to Free Cash Flow54.72
EV to Operating Cash Flow20.51
Balance Sheet
Alembic Pharmaceuticals Limited has ₹1.96B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹1.96B billion.
Cash & Marketable Securities₹1.96B
Total Debt₹0.00
Net Cash₹1.96B
Net Cash Per Share₹9.99
Tangible Book Value Per Share₹273.83
Margins
Gross margin is 44.47%, with operating margin of 10.89%, and net profit margin of 9.19%.
Gross Margin44.47%
Operating Margin10.89%
Pretax Margin9.45%
Net Profit Margin9.19%
EBITDA Margin15.06%
EBIT Margin10.72%
Analyst Forecast
The average price target for Alembic Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast14.12%
EPS Growth Forecast14.98%